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BACKGROUND & AIMS: Direct-acting antivirals that target
nonstructural protein 5A (NS5A), such as daclatasvir, have high
potency against the hepatitis C virus (HCV). They are promising
clinical candidates, yet little is known about their antiviral mech-
anisms. We investigated the mechanisms of daclatasvir de-
rivatives. METHODS: We used a combination of biochemical
assays, in silico docking models, and high-resolution imaging to
investigate inhibitor-induced changes in properties of NS5A,
including its interaction with phosphatidylinositol-4 kinase IIIa
and induction of the membranous web, which is the site of HCV
replication. Analyses were conducted with replicons, infectious
virus, and human hepatoma cells that express a HCV polyprotein.
Studies included a set of daclatasvir derivatives and HCV vari-
ants with the NS5A inhibitor class-deﬁning resistance mutation
Y93H. RESULTS: NS5A inhibitors did not affect NS5A stability or
dimerization. A daclatasvir derivative interacted with NS5A and
molecular docking studies revealed a plausible mode by which
the inhibitor bound to NS5A dimers. This interaction was
impaired in mutant forms of NS5A that are resistant to dacla-
tavir, providing a possible explanation for the reduced sensitivity
of the HCV variants to this drug. Potent NS5A inhibitors were
found to block HCV replication by preventing formation of the
membranous web, which was not linked to an inhibition of
phosphatidylinositol-4 kinase IIIa. Correlative light-electron mi-
croscopy revealed unequivocally that NS5A inhibitors had no
overall effect on the subcellular distribution of NS5A, but
completely prevented biogenesis of the membranous web.
CONCLUSIONS: Highly potent inhibitors of NS5A, such as
daclatasvir, block replication of HCV RNA at the stage of mem-
branous web biogenesis—a new paradigm in antiviral therapy.
Keywords: Drug Mechanism; Chronic Hepatitis C; Viral Repli-
cation; Viral Replication Factory.
nfection with the hepatitis C virus (HCV) is a major0016-5085
http://dx.doi.org/10.1053/j.gastro.2014.07.019Icause of chronic liver disease and accounts for a large
proportion of liver cirrhosis cases and hepatocellularcarcinomas.1 Given an estimated 130 to 170 million infected
individuals worldwide and the high prevalence in industri-
alized countries, intensive efforts are being undertaken to
improve antiviral therapy.2 Very recently, HCV-speciﬁc
direct-acting antiviral drugs have become available that
allow virus elimination in the majority of treated patients,
however, drug resistance, incomplete genotype coverage,
and high costs are important limitations.3
HCV is a plus-strand RNA virus encoding a single poly-
protein that is proteolytically cleaved into 10 different
products (reviewed in Moradpour and Penin4). Of these,
nonstructural protein (NS) 3, NS4A, NS4B, NS5A, and NS5B
form a multiprotein complex mediating viral replication.
Like all plus-strand RNA viruses, HCV replication occurs in
cytoplasmic membranous factories. These are composed
primarily of double- and multimembrane vesicles forming a
heterogeneous meshwork designated “membranous web”
(MW).5,6 It is induced by a concerted action of HCV replicase
proteins6 together with host cell factors, most notably
phosphatidylinositol-4 kinase IIIa (PI4KIIIa).7,8 This lipid
kinase is recruited to viral replication sites by interaction
with NS5A, leading to the accumulation of high amounts of
PI4-phosphate (PI4P) at intracellular membranes.
NS5A is a multifunctional zinc-binding protein (reviewed
in Moradpour and Penin4). It is phosphorylated at several
sites by cellular kinases giving rise to basal (p56) and
hyperphosphorylated (p58) NS5A. Phosphorylation is
thought to regulate the multitude of NS5A functions,
including RNA binding and self-interaction. NS5A is
composed of an N-terminal amphipathic a-helix (AH) teth-
ering the protein to membranes,9 a highly structured domain
I (DI)10,11 and 2 intrinsically unfolded “domains”with limited
November 2014 HCV NS5A Inhibitors Block Membranous Web 1095sequence conservation between genotypes (reviewed in
Moradpour and Penin4). Four x-ray crystal structures of
NS5A DI of genotype 1 revealed virtually identical monomer
conformations, but distinct dimer organizations that have
been proposed to form multimeric complexes.10–12
High-throughput screening with HCV replicons and
optimization of lead compounds led to the development of
highly potent direct-acting antiviral drugs targeting NS5A
and efﬁciently inhibiting viral RNA synthesis and virus
assembly.13–15 As illustrated with daclatasvir, the ﬁrst in-
hibitor of this class, these drugs are characterized by a
symmetric structure with a rigid central core and unparal-
leled antiviral activity. Their mode of action is still debated
and several hypotheses have been put forward16–18; how-
ever, none of these explain the extremely high potency. In
the present study, we demonstrate that highly potent NS5A
inhibitors efﬁciently block biogenesis of membranous HCV
replication factories.BA
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Compounds
In this study, we used NS5A inhibitors BMS-790052
(daclatasvir), BMS-553, BMS-671, BMS-690; the PI4KIIIa in-
hibitor AL-9 (kindly provided by Francesco Peri, Petra Ned-
dermann, and Raffaele De Francesco, Fondazione Istituto
Nazionale Genetica Molecolare, Milano, Italy); and the NS3
protease inhibitor telaprevir (see Supplementary Materials and
Methods).
Electron Microscopy
Huh7-Lunet/T7 cells transfected with HCV NS3-5B
expression constructs containing the 30 untranslated region
were treated with given inhibitors, ﬁxed, embedded into epon
resin, and sections were examined by transmission electron
microscopy. Additional details are given in the Supplementary
Materials and Methods.
In Silico Docking Experiments
Docking experiments were performed using the Sybyl X 2.0
program included in the molecular modeling suite software
package (Tripos, Inc.) as detailed in Supplementary Materials
and Methods.Results
Impact of a Daclatasvir Derivative on the Hepatitis
C Virus Replication Cycle
To determine the mode of action of highly active NS5A
inhibitors, we used the daclatasvir derivative BMS-553,
available to us when we started this study and sharing the
symmetrical molecular scaffold (Figure 1A). BMS-553
inhibited replication of genotype 1b- and 2a-derived repli-
cons with a 50% effective concentration (EC50) of approxi-
mately 20 pM and approximately 30 pM, respectively,
comparable with daclatasvir,14 and was similarly active
against the JFH1-derived full-length reporter virus JcR-2a7
(EC50 approximately 50 pM; Supplementary Figure 1A).Cell viability assays conﬁrmed that BMS-553 concentrations
were noncytotoxic up to 16,000-fold EC90 (Supplementary
Figure 1B).
Unless otherwise stated, for all subsequent experiments
we used derivatives of the JFH1 isolate because it supports
efﬁcient virus production. Time-course experiments revealed
rapid suppression of HCV replication that was even more
pronounced when cells were also pretreated with BMS-553
for 2 hours before infection (Figure 1B). Selection for BMS-
553 resistance with Jc1 virus (not shown) revealed the
NS5A Y93H mutation that was found in all tested genotypes
in vitro and in vivo treated with daclatasvir,19,20 arguing for
the same mode of action of both compounds. This mutation
increases resistance of JFH1-derived replicons or virus
approximately 750- and 1000-fold, respectively.21 Consistent
with earlier reports, virus production was already sup-
pressed 24 hours after treatment and much stronger than
expected from replication inhibition (Figure 1C), corrobo-
rating that NS5A inhibitors have a bimodal action, that is,
impairing RNA replication and assembly of infectious HCV
particles.15,22 Importantly, replication and assembly of the
Y93H mutant was unaffected by the compound, suggesting
that a property of NS5A common to both processes is tar-
geted by highly potent NS5A inhibitors.Impact of Nonstructural Protein 5A Inhibitor on
Protein Stability and Self-Interaction
Next, we determined the impact of BMS-553 on NS5A
phosphorylation status and protein stability in a Jc1 virus
system. Consistent with an earlier study,16 p58 abundance
was reduced, arguing for impaired NS5A hyper-
phosphorylation (Supplementary Figure 2). This was not the
case with the Y93H mutant demonstrating speciﬁcity of this
phenotype. However, alteration of hyperphosphorylation is
not unique to NS5A inhibitors and was also found when
polyprotein cleavage was blocked with telaprevir
(Supplementary Figure 2).
Owing to the high potency of NS5A inhibitors, mecha-
nistic studies are ﬂawed by the rapid loss of viral RNA and
protein when using HCV replication systems. To circumvent
this problem, for further analyses, we utilized an
expression-based system supporting efﬁcient expression of
viral proteins and enabling mechanistic studies independent
from RNA replication (Supplementary Figure 3A).6 Given
the reported binding of NS5A to the 30 untranslated region
of the HCV genome, this RNA element was included in all
expression constructs.23 In this system, an approximately
17-fold higher concentration of NS5A inhibitor is required
to induce phenotypic effects comparable with HCV repli-
cons,17 therefore, we used 5 and 50 EC90 for most
subsequent analyses. We found that stability of NS5A was
unaltered by BMS-553, as neither steady-state levels of
NS5A (Figure 1D) nor half-lives of the phosphovariants
were affected (Supplementary Figure 3B–D).
Because of the symmetric nature of potent NS5A in-
hibitors, it has been proposed that these compounds might
block NS5A self-interaction.24 To address this assumption,
we conducted Förster resonance energy transfer–based
Figure 1. Potent inhibition of HCV replication by daclatasvir-like inhibitor BMS-553. (A) Structures of BMS-790052 (daclatasvir)
and BMS-553. (B) Time course of replication inhibition with pre- and post-treatment setup. Huh7.5 cells were inoculated with
JcR-2a and 48 hours later BMS-553 (50 EC90) was added until cell harvest at given time points (post-treatment; red circles).
For pretreatment, compound was added to culture medium for 2 hours before inoculation and 48 hours after infection until cell
harvest (black circles). Luciferase activity was measured and normalized to mock-treated cells (white circles; set to 100%). (C)
Impact of BMS-553 on virus production. Huh7.5 cells were infected (one 50% tissue culture infective dose [TCID50]/cell) with
wt HCV (chimera Jc1) or the resistant mutant Jc1 Y93H (left and right panel, respectively). Forty-eight hours later, cells were
treated with 5 or 50 EC90 BMS-553 or mock-treated with dimethyl sulfoxide (DMSO) and harvested after 24, 36, and 48
hours of treatment. Titers of infectious virus contained in cell lysates (intracellular infectivity) or culture supernatants (extra-
cellular infectivity) were determined by limiting dilution assay (TCID50). (D) NS5A protein levels detected in Huh7-Lunet/T7 cells
transfected with wt or Y93H-containing NS3-5B expression constructs (top panel). Cells were treated at the time of trans-
fection or 6 hours thereafter with 5 or 50 EC90 BMS-553 (co-treatment and posttreatment, respectively) for 20 hours. NS5A
in cell lysates was detected by Western blot. Numbers below each lane: NS5A amounts, normalized to the respective b-actin
value. DMSO-treated samples were set to 100%. (E) NS5A–NS5A co-immunoprecipitation is not affected by BMS-553. Six
hours after transfection of tandem-NS5A expression constructs (top panel), cells were mock-treated or treated with 50 EC90
BMS-553 for 20 hours. Cell lysates (INPUT) and eluates of HA-speciﬁc immunoprecipitation were analyzed by Western blot
using HA- and green ﬂuorescent protein (gfp)-speciﬁc antibodies. 2a, peptide of foot and mouth disease virus. Constructs
contained either 2 wt NS5As (tandem NS5A wt–wt) or 2 resistant variants (tandem Y93H–Y93H). A nontandem NS5A-gfp
construct served as pull-down speciﬁcity control.
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November 2014 HCV NS5A Inhibitors Block Membranous Web 1097experiments using NS5A proteins encompassing the N-ter-
minal AH and DI (aa 1–199). DI is sufﬁcient to form
homodimers10–12 and, indeed, NS5A self-interaction was
readily detectable but unaffected by BMS-553 treatment
(not shown).
Previous studies have shown that properly phosphory-
lated and fully functional NS5A requires its expression in the
context of an NS3–5A minimal polyprotein.25 Therefore, to
determine the impact of BMS-553 on self-interaction of NS5A
in its native state, we co-expressed 2 independent NS3-5B
polyproteins with differently tagged NS5A; however, no
NS5A dimerization was detected (not shown). Assuming that
NS5A dimerization “in trans” might be inefﬁcient, we gener-
ated a “tandem NS5A” construct (Supplementary Figure 4A).
This tandem NS5A cassette encoding 2 differently tagged
NS5As was fully functional as it supported replication and
was sensitive to inhibitor treatment (Supplementary
Figure 4B and C). When this tandem-NS5A cassette
was studied in our expression system, we clearly observed
NS5A self-interaction, but it was not affected by BMS-553
(Figure 1E).BA
SI
C
AN
D
TR
AN
SL
AT
IO
NA
L
LI
VE
RInteraction Between Nonstructural Protein 5A
and Daclatasvir-Like Inhibitors
To determine the mechanism of NS5A inhibitor resis-
tance, we utilized 2 biotin-conjugated stereoisomers
(Figure 2A). Although the (S,S)-isomer BMS-671 efﬁciently
blocked replication of genotype 1b and 2a replicons with
EC50 values of approximately 38 nM and 136 nM, respec-
tively, the control (R,R)-isomer BMS-690 was completely
inactive (Supplementary Figure 1C). To determine
NS5A–compound interaction, Huh7-Lunet/T7 cells
expressing the NS3-5B polyprotein were incubated with
compound and streptavidin-speciﬁc afﬁnity capture was
performed. Approximately 3% of total NS5A was captured
with the biologically active BMS-671, and no signal was
detected in complexes captured with the inactive isomer
(Figure 2B), as shown previously.14 Binding of active com-
pound was reduced approximately 30% in case of the Y93H
mutant likely accounting, at least in part, for resistance.
A clariﬁcation of the molecular mechanism by which
potent NS5A inhibitors interfere with NS5A function is
complicated by the lack of known enzymatic activities and
adequate biochemical assays to monitor structural changes
of membrane-associated full-length NS5A. To overcome this
limitation, we conducted in silico docking simulations using
the Sybyl program to probe putative binding sites of BMS-
553 and daclatasvir on available NS5A DI dimer crystal
structures (Figure 2C–E).10–12 In contrast to previous stud-
ies,26–29 no modeling for the positioning of the AH relative to
DI was done because numerous possibilities exist, as
described recently,28 but none is supported by experimental
data. In addition, daclatasvir was recently shown to bind
efﬁciently to NS5A aa 33–202 (Kd 8 nM), but less tightly to
NS5A aa 26–202 (Kd 210 nM), suggesting that the segment
connecting AH and DI might compete for the same binding
site as the inhibitor.29 Although the primary resistance res-
idue Y93 lies on the bottom of a profound cleft in the so-called“back-to-back” dimer structure11 (Figure 2D), it resides on a
rather ﬂat surface in the “clam-like” dimer, which does
not exhibit a binding cleft on that side (Figure 2E).10 Never-
theless, in both structures, Y93 is supposed to reside on the
membrane-proximal surface of the dimer. In the back-to-back
dimer, daclatasvir and its derivatives dock at nearly the same
site in the cleft and interact with the side chain of Y93 by
stacking of aromatic rings, corroborating a similar mode of
action (Figure 2D, middle and right panels; Supplementary
Figure 5 and Supplementary Video M1). Consistent with
our experimental data, the inactive (R,R)-isomer BMS 690
docks perpendicularly to this cleft (Supplementary Video
M1), arguing for an essential role of this cleft as inhibitor
binding site. This cleft is located at the junction of both DI
subunits with docked BMS-553 and daclatasvir exhibiting
close contacts with residues at the dimer interface
(Supplementary Figure 6A), for example, aa 54 that is a site
for secondary resistance mutations.30 Importantly, one
“edge” of BMS-553 and daclatasvir partly extends outside the
cleft and contacts aa 58, also reported to be affected by sec-
ondary resistance mutations (Figure 2D, right panel and
Supplementary Figure 6A).30 This location and the involve-
ment of residue 58 suggest that these compounds might
affect NS5A multimerization, which has been proposed
earlier.11 Alternatively, the binding of daclatasvir or BMS-553
at this location might perturb the positioning of the N-ter-
minal AH on DI in the model recently proposed,28 affecting
proper positioning and/or folding of the linker segment
connecting DI with the AH (Supplementary Figure 5A). This
hypothesis is supported by the docking of both inhibitors
close to the N-terminus of DI (aa 32 and 33) and by several
daclatasvir resistance mutations residing in this connecting
region, especially at aa 28, 30, 31, and 32.30
In the clam-like DI dimer,10 no binding cleft is present.
BMS-553 and daclatasvir dock into the same area
(Figure 2E; Supplementary Figure 6B and 7; Supplementary
Video M2), which includes aa 54 and 93 and corresponds to
the area forming one border of the cleft observed at
the interface of the back-to-back structure. In addition,
both compounds are located at the membrane-proximal
surface, eventually disturbing positioning and/or folding
of the N-terminal linker segment connecting DI with AH
(Supplementary Figure 7).
Docking experiments conducted on the recently re-
ported head-to-head DI dimer revealed that all NS5A in-
hibitors docked into the cleft at the dimer interface in a
comparable manner, similar to that reported (data not
shown).12 However, the relevance of this inhibitor binding
cleft is unclear because Y93 is not directly in contact with
the docked molecules.Impact of Daclatasvir-Like Inhibitor on
Phosphatidylinositol-4 Kinase IIIa Properties
HCV replication strictly depends on the host cell kinase
PI4KIIIa, which physically interacts with NS5A and modu-
lates NS5A phosphorylation.7,31 It was also shown that
4-anilino quinazolines, such as AL-9, which were formerly
classiﬁed as NS5A inhibitors, are inhibitors of PI4KIIIa.32
Figure 2. NS5A-inhibitor interaction. (A) Structures of biotin-tagged compounds BMS-671 and BMS-690. Stereoisomeric
differences, red arrows; biotin-tag, gray. (B) Huh7-Lunet/T7 cells transfected with wt or resistant (Y93H) NS3-5B expression
constructs were treated 6 hours post transfection with 1 mM inhibitor (approximately 1 EC90 for BMS-671) for a total of 20
hours. Cell lysates (INPUT) and streptavidin-speciﬁc immunoprecipitation eluates were analyzed by Western blot. Numbers:
ratio captured NS5A/input. wt set to 100%. (C) Stick representations of daclatasvir and BMS-553. (D, E) In silico docking of
NS5A DI dimers with daclatasvir-like inhibitors. (D) Back-to-back dimer structure of NS5A DI (Protein Data Bank [PDB]
accession no. 3FQQ)11 showing high-ranked poses of BMS-553 (red) and daclatasvir (violet) docked into the cleft located at
the junction of the 2 subunits (yellow and light gray). Note that symmetrically docked BMS-553 and daclatasvir molecules,
relative to the cleft center, were also observed (Supplementary Figure 5). Residues associated with primary or secondary
daclatasvir resistance are shown as van der Waals spheres. Left panel shows ribbon representation of the dimer and its
presumed proximity to the membrane surface. Dashed lines: linker segment connecting DI with N-terminal membrane-
anchoring AH (details in Supplementary Figures 5 and 6A). Middle panel: membrane-proximal view; right panel: enlarged
side view. (E) Clam-like dimer structure of NS5A DI10 showing representative high-ranked poses of BMS-553 and daclatasvir
analogous to (D). Both molecules mainly dock on the rather ﬂat surface of subunit A (cyan) of the clam-like dimer (cyan and
mauve monomers). Note the slightly asymmetric docking relative to the dimer symmetry, resulting from subtle subunit
structure asymmetries in the crystal structure (details in Supplementary Figures 6B and 7). Figures were generated using Visual
Molecular Dynamics and structural coordinates deposited in the PDB; rendering with POV-Ray.
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Figure 3. Impact of BMS-553 on PI4KIIIa. (A) In vitro lipid kinase activity of PI4KIIIa is not affected by BMS-553, but blocked by
AL-9. Twenty nanograms recombinant PI4KIIIa was assayed with dimethyl sulfoxide (DMSO), BMS-553, or AL-9 (5 or 50
EC50, each). A representative assay with mean values of triplicate measurements is shown. Data represent counts per minute
(cpm) after background subtraction. (B) Left panel: Huh7-Lunet/T7 cells were transfected with indicated constructs and either
mock-treated or incubated with 5 or 50 EC90 BMS-553, starting 6 hours after transfection until cell harvest. Proteins were
radiolabeled metabolically in the presence of inhibitor and immunoprecipitation was performed using NS5A- (lane 1–5) or HA-
speciﬁc antibodies (lane 6). Control cells express only HA-PI4KIIIa (lane 4, lane 6) or only NS3-5B (lane 5). Captured complexes
were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis and phosphor-imaging. Right panel: quantiﬁ-
cation of phosphor-images (ratio of PI4KIIIa/NS5A after background subtraction, relative to mock-treated cells). (C) Same as in
(B), but using NS3-5B Y93H polyprotein. (D) Immunoﬂuorescence staining of NS5A and PI4P in Huh7-Lunet/T7 cells
expressing wt or Y93H NS3-5B and treated with DMSO (Mock) or 50 EC90 BMS-553 (starting 6 hours post transfection for 20
hours). Nuclear DNA was stained with 40,6-diamidino-2-phenylindole. Representative images and PI4P-speciﬁc intensity
density (IntDen) in arbitrary units (AU) are shown for >40 cells of 3 independent experiments. *P < .01; **P < .001; ***P < .0001.
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puriﬁed PI4KIIIa in vitro, excluding this possible mode of
action (Figure 3A).
NS5A is critically involved in activation of PI4KIIIa ki-
nase activity, resulting in massive accumulation of intra-
cellular PI4P levels.7,8 To determine whether BMS-553
inhibits PI4KIIIa–NS5A interaction, we conducted colocali-
zation and coprecipitation experiments. Colocalization was
not affected by BMS-553 treatment (Supplementary
Figure 8). However, interaction of the kinase with wild-
type (wt) NS5A, but not the resistant mutant, was reduced
at highest BMS-553 concentrations (Figure 3B and C).
Next, we evaluated whether reduced NS5A-PI4KIIIa
interaction might affect kinase activation in vitro. Because
NS5A inhibitors were reported to bind to NS5A only intra-
cellularly, but not to puriﬁed protein,18 we coexpressed
PI4KIIIa and NS3-5B in the presence or absence of BMS-553.
PI4KIIIa was captured by immunoprecipitation either
directly or by coprecipitation with NS5A, and lipid
kinase activity was determined. PI4KIIIa activity was not
affected by inhibitor treatment in any condition we tested
(Supplementary Figure 9A). Because it was not clear whether
kinase activation by HCV had been retained during the pu-
riﬁcation process, we additionally determined amount and
intracellular distribution of PI4P as readout for NS5A-
mediated PI4KIIIa activation (Figure 3D). As described
earlier, cells expressing the HCV polyprotein contained
signiﬁcantly elevated amounts of intracellular PI4P, which
were reduced dose dependently by BMS-553. This reduction
was not observed with the Y93H resistance mutant
(Figure 3D), pointing to speciﬁc inhibition of NS5A-
dependent activation of PI4KIIIa by BMS-553. Therefore,
potent NS5A inhibitors reduce NS5A-mediated intracellular
accumulation of PI4P, which might be due in part to impaired
NS5A-PI4KIIIa interaction.31Daclatasvir-Like Nonstructural Protein 5A
Inhibitor Blocks Membranous Web Formation
Independent of RNA Replication
Given the important role of NS5A and PI4KIIIa for MW
formation and morphology,6,7,31 we examined HCV-induced
membrane alterations in cells expressing either wt or
Y93H-containing NS3-5B polyprotein after BMS-553 treat-
ment. Of note, this expression system induces membrane
rearrangementswell, comparablewith those detected in cells
containing a functional HCV genome (Supplementary
Figure 10).6 Treatment of polyprotein-expressing cells from
6 hours post transfection, referred to as “posttreatment,”
affected neither NS5A expression (Figure 1D, right panel) nor
the number of NS5A-expressing cells (SupplementaryFigure 4. Daclatasvir-like NS5A inhibitor alters MW biogenesis. (
Y93H NS3-5B polyprotein. Cells were treated with dimethyl su
(5 or 50 EC50), starting 6 hours after transfection for 20
Regions encircled with yellow lines highlight MW structures,
diameter (left panel) and number (right panel). Per condition we
DMV number per surface area using Image J and iTEM soft
approximately 10 EC90 of BMS-553. *P < .01; **P < .001; ***PFigure 11A). Electron microscopy analysis of mock-treated
cells revealed regular MW structures, most notably double
membrane vesicles (DMVs), the major MW constituents and
possible sites of HCV RNA replication6 (Figure 4A, top left
image). Upon treatment with BMS-553, the MW collapsed
concentration dependently and, after high-dose treatment,
only web remnants were detectable in few cells (Figure 4A).
In contrast, web morphology was unaffected in BMS-
553–treated cells expressing the Y93H-containing poly-
protein (Figure 4A, middle column), thus excluding
pleiotropic or cytopathic effects as a reason for web inhibi-
tion in wt polyprotein-expressing cells. In case of the
wt polyprotein DMV diameterwas reduced dose dependently
(Figure 4B), resembling the phenotype we had observed
earlier upon PI4KIIIa knock-down7 or upon treatment with
the PI4KIIIa inhibitor AL-932 (Figure 4A and B). Importantly,
DMV number was also massively reduced, both by BMS-553
and AL-9. In contrast, in cells expressing the Y93H mutant,
DMV diameter was slightly increased and DMV number was
not affected.
An even more striking effect was found with BMS-553
treatment, starting at the time point of transfection (referred
to as co-treatment). Again, NS5A expression per se, as well as
the number of NS5A-expressing cells, was not affected
(Figure 1D and Supplementary Figure 11B). However, MW
formation was no longer detectable in case of wt, and in cells
expressing the Y93H-containing polyprotein, vesicle forma-
tion was clearly detectable, even though their diameter was
smaller compared with mock-treated cells (Figure 5A and
Supplementary Figure 12). Importantly, in cells treated with
50 EC50 AL-9 (corresponding to 10 EC90 of BMS-553 as
determined by inhibition of HCV replication), DMVs were
still clearly detectable (Figure 5A and Supplementary
Figure 12), with no difference between post- or co-
treatment conditions (compare Figure 4 and Supplementary
Figure 12). These results suggest that abrogation of web for-
mation is a distinct phenotype that is notmediatedbyPI4KIIIa
inhibition. We also found no further impact of BMS-553
co-treatment on intracellular PI4P pools (Supplementary
Figure 9B) compared with posttreatment (Figure 3D).
To exclude the possibility that we had missed virus-
induced membrane rearrangements in inhibitor-treated
cells due to low/no expression of viral proteins in
analyzed cells, correlative light-electron microscopy was
applied. We used NS3-5B wt or Y93H polyproteins con-
taining a green ﬂuorescent protein insertion in DIII of NS5A
that does not interfere with replication competence.33 Upon
expression of these constructs in Huh7-Lunet/T7 cells, no
distinct difference in NS5A ﬂuorescence patterns was
detected between wt and resistance mutant in cells co-
treated with BMS-553 (Figure 5B and C, respectively).<
A) Detection of the HCV-induced MW in cells expressing wt or
lfoxide (DMSO) (Mock), BMS-553 (5 or 50 EC90), or AL-9
hours (posttreatment). Representative images are shown.
predominantly containing DMVs. (B) Quantiﬁcation of DMV
analyzed >60 DMVs for mean diameter and 6 cell proﬁles for
ware packages. Note that 50 EC50 AL-9 corresponds to
< .0001.
November 2014 HCV NS5A Inhibitors Block Membranous Web 1101
BA
SI
C
AN
D
TR
AN
SL
AT
IO
NA
L
LI
VE
R
Figure 5. Early treatment
with daclatasvir-like inhibi-
tor completely blocks MW
formation. (A) Quantiﬁca-
tion of DMV diameter (left
panel) and number (right
panel) as described in
Figure 4. Representative
electron microscopy (EM)
micrographs are shown in
Supplementary Figure 10.
(B) Correlative light electron
microscopyofHuh7-Lunet/
T7cells expressingwtNS3-
5B containing a green ﬂuo-
rescent protein (gfp)-tag in
NS5A DIII. Cells were co-
treated with 50 EC90
BMS-553 for 20 hours. Top
row, left panel: epiﬂuor-
escence microscopy of live
cells grown on gridded
coverslips; middle panel:
enlarged ﬂuorescence im-
age of the cell boxed in the
left (NS5Agfp, green); right
panel: merge of EM and
epiﬂuorescence image.
Yellow boxes: enlarged ar-
eas shown in the bottom.
(C) Same as in (B) using
cells expressing Y93H-
containing polyprotein.
Note that DMVs (blue
arrowheads) arewell visible.
LD, lipid droplet. *P < .01;
**P < .001; ***P < .0001.
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membrane rearrangements were detected in subcellular
regions containing low or high NS5A amounts (Figure 5B),
corroborating profound inhibition of MW formation by the
NS5A inhibitor. In contrast, in case of Y93H polyprotein,
DMVs were readily detected (Figure 5C). Importantly, the
sites of strong NS5A accumulation corresponded to areascontaining lipid droplets surrounded by DMV clusters,
consistent with the observed accumulation of NS5A in close
proximity of lipid droplets in inhibitor-treated cells
(Supplementary Figure 13).18
To conﬁrm inhibition of MW formation in a replication-
based system, we analyzed cells transfected with the Jc1
genome and treated with BMS-553. A reduction of DMV
Figure 6. Inhibition of MW
formation by BMS-553 in a
replication system. (A)
Detection of MW structures
in cells transfected with Jc1
wt or Jc1 Y93H RNA ge-
nomes. Forty-eight hours
after electroporation, cells
were treated for 4 hours or
12 hours with dimethyl
sulfoxide or 5 EC90 BMS-
553. Areas highlighted with
yellow lines or circles indi-
cate regions containing
DMVs. (B) Quantiﬁcation of
DMV diameter (left panel) or
number (right panel) as
described in Figure 4. (C)
Cells treated as described
in (A) were analyzed by
Western blot using NS5A-
or b-actin–speciﬁc anti-
bodies. Control cells:
co-treatment with 5 EC90,
starting directly after elec-
troporation (5co-t);mock-
transfected cells (empty).
(D) Immunoﬂuorescence
staining of NS5A in cells
treated as described. Nu-
clear DNA was stained
with 40,6-diamidino-2-
phenylindole. Representa-
tive images are shown. For
illustration purposes, im-
ages were autocontrasted
and merged using Image J.
NS5A, red; nuclear DNA,
blue. *P < .01; **P < .001;
***P < .0001.
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dramatic at 12 hours after BMS-553 treatment, which was
not found in Jc1 Y93H-transfected cells (Figure 6A and B).
Importantly, during these time periods, abundance and
subcellular distribution of NS5A were not affected (Figure 6C
and D). In addition, cells co-treated directly after Jc1 trans-
fection completely inhibited wt, but not the Y93H-resistant
mutant. In summary, these results demonstrate that a
potent daclatasvir-like NS5A inhibitor blocks biogenesis of
the MW, the presumed sites of HCV replication.Discussion
Disruption of the biogenesis of a virus-induced replica-
tion factory, which is a central element for the replication of
all plus-strand RNA viruses,6 is a novel paradigm in antiviral
therapy. We show here that a daclatasvir-like inhibitor ab-
rogates formation of the MW, the presumed replication site
of HCV.
Molecular docking studies indicate that BMS-553 and
daclatasvir might bind to the supposed membrane-proximal
side of both the back-to-back and the clam-like dimer
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LIVERstructure of NS5A DI.10,11 Therefore, the inhibitors might
disturb positioning, folding, or ﬂexibility of the AH–DI linker
segment. Such conformational constraints might affect
interaction of NS5A with membranes or cellular proteins
and/or proper self-interaction as also proposed by
others.12,26,34 With respect to host cell proteins, NS5A ap-
pears to form different molecular complexes associated with
membranes and several of these interactions might be
disturbed upon inhibitor binding. Additionally, the loss of
PI4KIIIa activation resulting in clear reduction of intracel-
lular PI4P amounts provides one example. Interestingly,
mutations in NS5A DI interfering with functional NS5A-
PI4KIIIa interaction resulted in identical phenotypes as
compared with PI4KIIIa inhibition by AL-9, and also
impaired HCV replication.31 It therefore seems likely that
blocking functional NS5A-PI4KIIIa interaction contributes
to inhibition of HCV replication and high potency of
daclatasvir-like NS5A inhibitors.
Concerning self-interaction, our docking studies suggest
that daclatasvir and BMS-553 do not affect NS5A dimers,
consistent with our coprecipitation and recent results.29
However, NS5A might form multimers required for RNA
replication and eventually also assembly.11 Although
experimental data for their existence are lacking,
daclatasvir-like inhibitors might disrupt multimers and/or
their proper membrane association via AH, without affecting
dimers. This could explain high potency of NS5A inhibitors,
because low amounts might sufﬁce for “fragmentation” of
multimers and/or disturbing their correct assembly at the
membrane interface. Alternatively, NS5A inhibitors might
affect proper membrane association of NS5A dimers or
NS5A–RNA interaction, but it is unclear how this translates
into high antiviral potency.29
Whatever the structural alterations are, they severely
compromise NS5A-mediated membrane rearrangements. By
using correlative light electron microscopy, we demonstrate
that MW formation is blocked, even though cells express high
amounts of HCV proteins. We recently demonstrated that
proper web formation requires the concerted action of all
HCV replicase factors, with NS5A being the only one inducing
DMV-like structures.6 Interestingly, in cells treated with
daclatasvir-like inhibitor, no HCV-speciﬁc membrane rear-
rangement was detected, suggesting that NS5A inhibition
might alter membrane activity of the other HCV proteins.
Consistent with our results, it has recently been reported
that NS5A inhibitors block both RNA replication and as-
sembly of infectious HCV particles.22 In addition, based on
the rather slow decline of viral RNA, it is assumed that NS5A
inhibitors only affect de novo formation of new replicase
complexes, and established ones are not addressed.
Although this is a valid assumption, we observed a sur-
prisingly fast loss of DMVs upon NS5A inhibitor treatment in
cells containing replicating HCV genomes. These results
suggest that DMVs either have a very fast turnover or they
are actively degraded upon drug treatment.
In conclusion, we demonstrate that highly potent NS5A
inhibitors disrupt MW formation independent of RNA
replication and, therefore, at a very early stage of the viral
replication cycle. Although the exact impact of these drugson NS5A structure remains to be determined, the block of
biogenesis of the membranous HCV replication factory likely
deﬁnes a major mode-of-action of these clinically highly
promising direct-acting antiviral drugs.Supplementary Material
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Supplementary Materials and Methods
Antibodies
The following primary antibodies with given speciﬁcities
were used in this study: glyceraldehyde-3-phosphate dehy-
drogenase (mouse monoclonal IgG1, Santa Cruz Biotech-
nology, Santa Cruz, CA; sc-47724; 1:1000); b-actin (mouse
monoclonal IgG2a, Sigma-Aldrich, St Louis, MO; A2228,
1:5000); green ﬂuorescent protein (gfp) (mouse monoclonal
IgG2a, Clontech, Mountain View, CA; 632381, 1:1000); HA
(mouse monoclonal IgG1, Sigma-Aldrich; H3663, 1:1000 for
Western blot and 1:200 for immunoﬂuorescence); PI4P
(mouse monoclonal IgM, Echelon, Salt Lake City, UT; Z-P004,
1:200); NS5A 9E10 (mouse monoclonal IgG2a, 1:10,000 for
Western blot and 1:1000 for immunoﬂuorescence; kindly
provided by Charles M. Rice, Rockefeller University, New
York, NY); NS5A 4952 (rabbit polyclonal, 1:2001); and NS3
(mouse monoclonal, 1:100; generated in cooperation with
Hengli Tang).2 The following secondary antibodies with
given speciﬁcities were used: anti-mouse coupled to horse-
radish peroxidase (goat polyclonal IgG, Sigma-Aldrich;
A4416, 1:10,000); anti-rabbit horseradish peroxidase (goat
polyclonal IgG, Sigma-Aldrich; A6154, 1:25,000), Alexa Fluor
488 goat anti-mouse IgG (HþL); Alexa Fluor 488 goat anti-
mouse IgM (m-chain); Alexa Fluor 568 donkey anti-mouse
IgG; and Alexa Fluor 568 goat anti-rabbit IgG (HþL) anti-
body (Molecular Probes, Invitrogen, Carlsbad, CA).
Cell Culture
Huh7.5,3 Huh7-Lunet,4 Huh7-Lunet/T7,2 and U2-OS5
cells were grown in Dulbecco’s modiﬁed minimal essential
medium (DMEM; Life Technologies, Norwalk, CT) supple-
mented with 2 mM L-glutamine, nonessential amino acids,
100 U/mL penicillin, 100 mg/mL streptomycin, and 10%
fetal calf serum (DMEM complete [cplt]). Save for U2-OS, all
cell lines are derived from the human hepatoma cell line
Huh7,6,7 which is highly permissive for HCV. Huh7-Lunet/
T7 cells were cultured in the presence of 5 mg/mL zeocin or
10 mg/mL blasticidin and used for transfection of pTM-
based expression plasmids. Huh7-Lunet cells containing
persistent, selectable subgenomic reporter replicons of ge-
notype 2a (LucUbiNeo_JFH1, designated replicon JFH1) and
genotype 1b (LucUbiNeo_Con1ET, designated replicon
Con1ET) have been described earlier.8,9 Medium was sup-
plemented with 1 mg/mL or 0.5 mg/mL geneticin (G418)
for genotype 2a and 1b replicon cell lines, respectively.
Compounds
NS5A inhibitors BMS-790052 (daclatasvir), BMS-553,
BMS-671, BMS-690 were obtained from Bristol-Myers
Squibb (Wallingford Center, CT). AL-9 was kindly provided
by Francesco Peri (Department of Biotechnology and Bio-
sciences, University of Milano-Bicocca, Milano, Italy), Petra
Neddermann and Raffaele De Francesco (INGM–Istituto
Nazionale Genetica Molecolare Romeo ed Enrica Invernizzi,
Milano, Italy). The NS3 protease inhibitor telaprevir was
obtained from Shanghai Research Institute of Chemical In-
dustry Testing Center. EC50 and EC90 values for BMS-553,
BMS-671, and BMS-690 were determined in the present
study; EC50 values of AL-9 and telaprevir were taken from
previous publications.10,11 All inhibitors were dissolved in
dimethyl sulfoxide (DMSO). Culturemedium ofmock-treated
cells contained DMSO corresponding to the highest inhibitor
concentration used in the respective assay.
Plasmid Constructs
All nucleotide and amino acid numbers refer to the JFH1
and the Con1 genome (GenBank accession no. AB047639
and AJ238799, respectively). Subgenomic reporter repli-
cons pFK_i389Luc_NS3-30_JFH1_dg (designated sgJFH1-Luc)
and the replication-deﬁcient NS5B mutant pFK_i389-
Luc_NS3-30_DGDD_JFH1_dg (designated sgJFH1-Luc DGDD),
as well as full-length reporter virus pFK_i389RLuc2a_Core-
30-Jc1 (designated JcR-2a), and chimera pFK_Jc1_dg (desig-
nated Jc1) were described earlier.12–16 Constructs such as
pTM_NS3-30_JFH1 used for T7 polymerase-based expression
of the HCV replicase proteins (NS3-NS5B) in Huh7-Lunet/
T7 cells have been described previously.2 In this plasmid,
the NS3-5B coding region is ﬂanked by the 30 untranslated
region that was included in all polyprotein expression
constructs because of the binding of NS5A to the 30 un-
translated region.17 The expression construct pTM_HA-PI4K
and the plasmids used for FRET assays have been described
elsewhere.12,18,19 To create the resistance mutation Y93H
(number refers to amino acid residue 93 of NS5A), poly-
merase chain reaction (PCR)-based site-directed mutagen-
esis was performed using the following primers: S/2a 5A
Y93H (50-cta tca att gcc aca acg gag g-30) and A/2a 5A Y93H
(50-cct cag tgt ggc aat tga tag-30). NS5A HA- or Flag-tagged
constructs (pTM- or pFK-based) were generated by over-
lap PCR. Both tags are ﬂanked by a ﬂexible linker and
inserted into NS5A DII at amino acid position 261 of NS5A.
This insertion does not affect HCV RNA replication of ge-
notype 1b replicons.20 Insertion of gfp into DIII of NS5A has
been described elsewhere; this insertion does not affect
RNA replication and reduces virus production only mod-
erately.13–16 To generate the tandem-NS5A construct
pTM_NS3-5B_NS5A-HA_2a_NS5A-gfp_JFH1 (designated tan-
dem NS5A) we performed 2 separate PCRs: PCR 1 with
sense primer S/HA (50- cta gag gcg gct atc cgt atg -30),
antisense primer A/NS5A2a (50-cac gtc ccc gca tgt tag aag
act tcc cct gcc ctc ggc tct gca gca cac ggt ggt atc gtc ctc ctcg
-30), and pTM_NS3-5B_5A-HA_JFH1 as template; PCR 2 with
primers S/NS5A 2a (50- aag tct tct aac atg cgg gga cgt gga
gga aaa tcc cgg gcc cat ggc ctc cgg atc ctg gct ccg cga c-30), A/
2a7414 (50- ccc gtg gac gag cct gca tca ccg -30) and
pTM_NS3-5B_5A-HA_JFH1 as template. Fragments were
combined by overlap PCR using S/HA and A/2a6992 (50-ggt
gtt gct gtg ggt ggt gca ggt-30) and the resulting DNA frag-
ment was digested with PmeI and SanDI. In a 3-factor
ligation, this fragment was combined with a 2.9-kb
SpeI–PmeI fragment isolated from pTM_NS3-5B_5A-
HA_JFH1 and a 9.6-kb SanDI–SpeI fragment derived from
pTM_NS3-5B_5A-gfp_JFH1. The ﬁnal construct is composed
of a T7 promoter sequence, an internal ribosome entry site
of the encephalomyocarditis virus, HCV NS3–NS5A-HA, the
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coding sequence of the 2a peptide of the foot-and-mouth
disease virus, NS5A-gfp, NS5B, and the T7 terminator
sequence. To determine functionality of the tandem NS5A
cassette with respect to RNA replication, it was inserted
into the sgJFH1-Luc replicon construct via HpaI and NsiI
restriction sites. Nucleotide sequences of all constructs
were veriﬁed by nucleotide sequence analysis.
In Vitro Transcription and RNA Transfection
Via Electroporation
Plasmid DNA (10 mg) was puriﬁed by phenol and
chloroform extraction. After ethanol precipitation, dis-
solved DNA was used for in vitro transcription reaction
that contained 80 mM HEPES (pH 7.5), 12 mM MgCl2, 2
mM spermidine, 40 mM dithiothreitol (DTT), 3.125 mM of
each nucleoside triphosphate, 1 U/mL RNasin (Promega,
Madison, WI), 0.6 U/mL T7 RNA polymerase (Promega) in a
total volume of 100 mL. After 2 hours incubation at 37C,
additional 0.3 U/mL T7 RNA polymerase were added and
the reaction was incubated for another 2–6 hours at 37C.
Transcription was terminated by treatment with 2U
RNase-free DNase (Promega) per mg plasmid DNA for 30
minutes at 37C. RNA was extracted with acidic phenol and
chloroform, precipitated with isopropanol at room tem-
perature, and dissolved in RNase-free water. Single-cell
suspensions (1–1.5  107 cells/mL) were prepared by
trypsinization and washing of Huh7-derived cells that
were resuspended in Cytomix21 containing 2 mM adeno-
sine triphosphate (ATP) and 5 mM glutathione. In vitro
transcripts (5 mg) were mixed with 400 mL cell suspension
and used for electroporation with a Gene Pulser system
(Bio-Rad, Hercules, CA) at 975 mF and 270 V in a 0.4-cm
cuvette (Bio-Rad). Cells were immediately diluted in
DMEM cplt and seeded as speciﬁed in the respective assay
sections.
Preparation of Virus Stocks
Huh7.5 cells were transfected with in vitro transcripts of
Jc1 wt, Jc1 Y93H, or JcR-2a wt by using electroporation.
Culture supernatant was harvested 24, 48, 72, and 96 hours
after transfection and cleared by passing through 0.45-mm
pore size ﬁlters. Virus from pooled supernatant was
precipitated using PEG-8000 as described elsewhere.22
Precipitate obtained after centrifugation (8000g, 2 hours,
4C) was resuspended in DMEM cplt. Infectivity titers were
determined by limiting dilution assay (50% tissue culture
infective dose [TCID50]).
Limiting Dilution Assay
For limiting-dilution assay Huh7.5 target cells were
used. Infected cells were detected by immunohistochem-
istry using the NS3-speciﬁc antibody 2E3 as described
elsewhere.23 Virus titers corresponding to the 50% tissue
culture infective dose (TCID50/mL) were calculated based
on the method of Spearman and Kärber.24,25
Jc1-Based Analyses
For determination of intra- and extracellular virus titers,
Huh7.5 cells were seeded into 12-well culture plates at a
density of 1  105 cells/well 1 day before infection with Jc1
or Jc1 Y93H (one TCID50/cell). Forty-eight hours post
infection, BMS-553 or DMSO-containing medium was added
for 24, 36, or 48 hours. At each time point, cells and su-
pernatant were harvested. Cells were washed once with
phosphate-buffered saline (PBS), trypsinized, resuspended
in 1 mL culture medium, and frozen at –20C. After 3 freeze-
and-thaw cycles consisting of rapid freezing in liquid ni-
trogen and thawing at 37C, cell debris was removed by
centrifugation at 10,000 rpm for 3 minutes. Samples were
analyzed by limiting dilution assay.
For NS5A quantiﬁcation and phosphorylation status
analysis by Western blot, Huh7.5 cells were seeded into a
12-well culture plate at a density of 3  105 cells/well.
One day later, cells were infected with Jc1 wt or Y93H
with 10 TCID50/cell. DMSO, BMS-553 (5 and 50 EC90)
or telaprevir (NS3 protease inhibitor; 5 EC50) was added
24 hours post infection. After 6, 12, and 24 hours of
treatment, cells were washed with PBS, sample buffer
(400 mM Tris [pH 8.8], 10 mM EDTA, 0.2% bromophe-
nolblue, 20% sucrose, 3% sodium dodecyl sulfate (SDS),
and 2% b-mercaptoethanol) was added and proteins were
analyzed by SDS polyacrylamide gel electrophoresis (PAGE)
and Western blot.
For analysis of DMV formation in a replication-
competent system, Huh7-Lunet cells were transfected
with in vitro transcribed Jc1 or Jc1 Y93H RNA or without
RNA (empty). Cells were seeded onto coverslips in 24-well
plates at a density of 1  105 cells/well. For one set of cells
(co-treatment control) treatment with 5 EC90 BMS-553
was started immediately at the time point of seeding. All
other samples were incubated for 48 hours before treat-
ment was started with DMSO or 5 EC90 BMS-553. After 4
hours or 12 hours treatment, cells were ﬁxed and prepared
for electron microscopy as described in the Electron Mi-
croscopy section of Supplementary Materials and Methods.
In addition, cells treated in parallel in the same way were
harvested and analyzed by Western blot or indirect
immunoﬂuorescence.
Cytotoxicity Assays for BMS-553, BMS-671,
and BMS-690
Huh7-Lunet cells were seeded into 96-well plates at a
density of 2.5  103 or 1.4  104 cells/well. One day later,
the respective compound was added at different concen-
trations and cells were incubated for 1 or 3 days. Cells and
supernatants were harvested and analyzed using the Cyto-
Tox 96 Non-Radioactive Cytotoxicity Assay kit (Promega)
according to the protocol of the manufacturer.
Dose–Response Assay Using Stable Replicon
Cell Lines and JcR-2a Reporter Virus
For dose–response assays using stable replicon cells,
LucUbiNeo_JFH1 or LucUbiNeo_Con1ET8,9 were seeded into
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a 12-well plate at a density of 4  104 cells/well. One day
later, BMS-553, BMS-671, or BMS-690 were added at
different concentrations. As mock control, DMSO was added
according to the highest inhibitor concentration used in the
assay. After 72 hours of treatment, cells were washed, lysed,
and analyzed by luciferase activity assay. EC50 and EC90
values were calculated using the GraphPad Prism software
package (version 5.03).
For dose–response assays using luciferase reporter vi-
rus JcR-2a, Huh7 cells were seeded 1 day before infection in
a 12-well culture dish at a density of 4  104 cells/well.
Eight hours post infection (5 TCID50/cell), cells were incu-
bated with given concentrations of BMS-553. As mock
control, DMSO was added corresponding to the highest in-
hibitor concentration used in the assay. After 72 hours of
treatment, cells were washed, lysed, and analyzed by
luciferase activity assay. EC50 and EC90 values were calcu-
lated using GraphPad Prism (version 5.03).
Full-Length Reporter Virus Replication Kinetics
For replication kinetics of reporter virus JcR-2a
(pFK_i389RLuc2a_Core-30-Jc1),12 Huh7.5 cells were seeded
into a 12-well culture plate at a density of 1  105 cells/
well. One day later cells were infected with JcR-2a (one
TCID50/cell). After 6 hours inoculation, medium was
replaced by fresh medium. In case of pretreatment, cells
were incubated in BMS-553-containing medium (50 EC90)
for 2 hours before inoculation with JcR-2a. In this case
medium was replaced by fresh DMEM directly before
infection. Forty-eight hours post infection, inhibitor was
added again for 6, 12, 24, and 48 hours before cells were
washed, ﬁxed, and analyzed by luciferase activity assay. In
case of posttreatment, cells were only treated with BMS-553
or DMSO (mock control) 48 hours post infection. Treatment
and assay analysis was performed as mentioned.
Transient Replication and Dose–Response
Assays of Tandem-Nonstructural
Protein 5A Replicons
Huh7-Lunet cells were transfected with in vitro tran-
scripts of the subgenomic tandem-NS5A reporter replicon
(sgJFH1-Luc tandem NS5A), the parental replicon sgJFH1-
Luc or the nonreplicating NS5B mutant sgJFH1-Luc DGDD.
After electroporation, cells were seeded into a 12-well
culture plate at a density of 1.4  105 cells/well. To
determine replication kinetics, cell lysates were harvested
4, 24, 48, and 72 hours after electroporation and analyzed
by luciferase activity assay. For dose–response assays, cells
were treated with different concentrations of BMS-553 one
day after seeding. As a mock control, cells were treated with
DMSO corresponding to the highest inhibitor concentration
used in the assay. Cell lysates were harvested after 72 hours
of treatment and analyzed by luciferase activity assay.
Luciferase Activity Assay
In case of stable replicon cells (LucUbiNeo_JFH1 and
LucUbiNeo_Con1ET),8,9 cells were washed with PBS and
lysed by freezing and thawing in 350 mL lysis buffer (0.1%
Triton X-100, 25 mM glycylglycine, 15 mM MgSO4, 4 mM
EGTA, and 1 mM DTT [pH 7.8]). One hundred microliters
lysate was mixed with 360 mL assay buffer (25 mM gly-
cylglycine, 15 mM MgSO4, 4 mM EGTA, 1 mM DTT, 2 mM
ATP, 15 mM K2PO4 [pH 7.8]) and 200 mL luciferin solution
(200 mM luciferin, 25 mM glycylglycine [pH 8.0]). Fireﬂy
luciferase activity was measured for 20 seconds in a
luminometer (Lumat LB9507, Berthold, Freiburg, Ger-
many). Measurements (relative light units) were normal-
ized to the corresponding values of DMSO-treated mock
cells, which were set to 100%. All measurements were done
in duplicates. For transient replication assays and dose–
response analyses of tandem NS5A constructs, luciferase
activity was determined in the same way. In case of full-
length reporter virus JcR-2a12 Renilla luciferase-based as-
says, 20 mL freeze-and-thaw lysate was mixed with 10 mL
assay buffer containing 1.4 mM Coelenterazine (PJK Chem-
ikalien, Kleinblittersdorf, Germany) and measured for 10
seconds. Replication efﬁciency was calculated by normal-
izing to values obtained with DMSO-treated mock cells,
which were set to 100%. Values obtained with noninfected
Huh7.5 cells (background values) were subtracted from all
measurements. All measurements were done in duplicates.
DNA Transfection
Huh7-Lunet/T7 cells were seeded as indicated in the
respective assay sections. Twenty-four hours later, cells
were transfected with pTM-based expression constructs by
using the TransITLT1 transfection reagent (Mirus Bio, LLC,
Madison, WI) according to the manufacturer’s protocol.
Immunoprecipitation Using Tandem
Nonstructural Protein 5A Constructs
Huh7-Lunet/T7 cells were seeded into 10-cm diameter
culture dishes at a density of 3 106 cells/dish. Twenty-four
hours later, cells were transfected with the tandem NS5A
expression construct as described. As speciﬁcity control for
immunoprecipitation (IP), a nontandem construct with
NS5A-gfp was transfected in parallel. Treatment with BMS-
553 or DMSO (mock control) was started 6 hours post
transfection for a total of 20 hours. Cells were washed with
PBS and lysed with 400 mL lysis buffer (20 mM Tris-HCl [pH
7.5], 100 mM NaCl, 0.1% NP-40, 50 mM NaF, 5 mM Na3VO4,
protease inhibitors; Roche, Nutley, NJ). Cleared lysates
(14,000 rpm, 45 minutes, 4C) were used for IP with agarose
beads coupled with HA-speciﬁc antibody (Sigma). After
overnight incubation at 4C, beads were washed three times
with lysis buffer and eluateswere analyzed by SDS-PAGE and
Western blot.
Immunoprecipitation With Biotin-
Tagged Compounds
Huh7-Lunet/T7 cells were seeded into 10-cm diameter
culture dishes at a density of 3  106 cells/well. One day
later, cells were transfected with wt polyprotein NS3-5B as
described. BMS-671 or BMS-690 was added to culture
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medium 6 hours post transfection at a concentration of
1 mM. After 20 hours of treatment, cells were washed with
PBS and lysed with 400 mL lysis buffer (50 mM Tris-HCl [pH
7.5], 150 mM NaCl, 1 mM EDTA, 0.1% NP-40, protease in-
hibitors; Roche) on ice for 45 minutes. Cleared lysates
(14,000 rpm, 45 minutes, 4C in a tabletop centrifuge) were
used for IP with streptavidin-coupled agarose beads (15 mL
bead slurry/sample). After overnight incubation at 4C
samples were washed 3 times with PBS and eluates were
analyzed by SDS-PAGE and Western blot.
Western Blot Analysis
Cell lysates or immunocomplexes were diluted with
sample buffer (400 mM Tris [pH 8.8], 10 mM EDTA, 0.2%
bromophenolblue, 20% sucrose, 3% SDS, and 2% b-
mercaptoethanol), heated for 5 minutes at 95C and pro-
teins were separated by SDS-PAGE. After electrophoresis
proteins were electrotransferred onto a polyvinylidene
diﬂuoride membrane (PerkinElmer Life Sciences, Waltham,
MA) for 1 hour. Membranes were blocked with PBS-Tween
(0.5%) supplemented with 5% dried milk for at least 1
hour, before 1-hour incubation with primary antibody. After
washing 3 times with PBS-Tween, secondary antibody
conjugated with horseradish-peroxidase was added and
incubated for 1 hour. Bound antibodies were detected after
several times washing with PBS-Tween using the Western
Lightning Plus-ECL kit (PerkinElmer) and visualized on
BioMax Light ﬁlms (Kodak, Rochester, NY).
Metabolic Radiolabeling of Proteins and
Nonstructural Protein 5A–Speciﬁc
Immunoprecipitation
Huh7-Lunet/T7 cells were seeded into 6-well culture
plates at a density of 34  105 cells/well. Around 24
hours later, cells were transfected as described. For pulse-
chase experiments, cells were washed with PBS 20 hours
after transfection and starved in methionine/cysteine-free
medium for 1 hour. Thereafter, cells were incubated for 1
hour with 1 mL methionine/cysteine-free medium, supple-
mented with 2 mM glutamine, 10 mM HEPES [pH 7.5], and
100 mCi/ml Express [35S] Protein Labeling Mix (Perki-
nElmer, Boston, MA). Cells were either washed and lysed
directly (30 minutes on ice) or incubated in DMEM cplt for
given chase periods before lysis. BMS-553 or DMSO treat-
ment was started during starvation and was continued
throughout the pulse-chase period. Cell lysates were pre-
pared using RIPA buffer (50 mM Tris [pH 7.5], 150 mM
NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, pro-
tease inhibitor cocktail; Roche) and cleared lysates (45-
minute centrifugation at 4C and 14,000 rpm in a tabletop
centrifuge) were used for IP with agarose beads coupled
with NS5A-speciﬁc monoclonal antibody 9E10. After over-
night incubation at 4C, immunocomplexes were washed 3
times with RIPA buffer and proteins were eluted with
sample buffer (400 mM Tris [pH 8.8], 10 mM EDTA, 0.2%
bromophenolblue, 20% sucrose, 3% SDS, and 2% b-
mercaptoethanol). Precipitated proteins were separated by
SDS-PAGE and analyzed by phospho-imaging. NS5A-speciﬁc
phospho-isoforms (p56 and p58) were quantiﬁed using the
QuantityOne software (version 4.6.2; BioRad, Munich,
Germany).
For IP of NS5A and PI4KIIIa, cells were seeded and
transfected as given. Treatment with BMS-553 or DMSO
was started 6 hours after transfection. After 16 hours of
treatment, cells were starved for 1 hour in methionine/
cysteine-free medium and incubated with radioactive me-
dium for 4 hours. BMS-553 or DMSO treatment was
continued throughout the starvation and labeling period.
Immunoprecipitation, visualization of proteins and quanti-
ﬁcation was performed as described.
In Vitro Lipid Kinase Assay
To measure in vitro lipid kinase activity, the following
standard reaction mix was prepared: 2 mM DTT, 10 mM
phosphatidylinositol/phosphoserine (Invitrogen), 10 mM
ATP (Roche), 10 mCi g-[32P] ATP (PerkinElmer), and lipid
kinase assay buffer (20 mM Tris/HCl [pH 7.4]; 5 mM MgCl2;
0.5 mM EGTA; 0.4% Triton-X 100) in a ﬁnal volume of
50 mL. DMSO (mock control), BMS-553 (5 or 50 EC90) or
AL-9 (5 or 50 EC50) was added and the reaction was
started by the addition of 20 ng PI4KIIIa (Millipore, Bill-
erica, MA). The reaction was incubated for 1 hour at room
temperature in a shaker (1000 rpm) and stopped by the
addition of 200 mL 1 M HCl. Subsequently, lipids were
extracted by the addition of 400 mL chloroform/methanol
suspension (1:1). After vortexing and centrifugation
(13,000 rpm, 2 minutes, room temperature) 125 mL of the
lower, organic phase was transferred into a scintillation
counting vial and 4 mL Ultima Gold (PerkinElmer) was
added. Incorporation of radioactive phosphate was
measured by using a liquid scintillation counter and is
expressed in counts per minute (cpm).
In Vitro Lipid Kinase Assay After
Immunoprecipitation
Huh7-Lunet/T7 cells were seeded into 15-cm diameter
culture dishes at a density of 7  106 cells/dish. Six hours
after transfection with pTM_NS3-30_JFH1 and/or pTM_HA-
PI4KIIIa, cells were treated with BMS-553 or DMSO (mock
control) for a total of 20 hours. Subsequently, cells were
washed with PBS and lysed on ice for 45 minutes with 1 mL
lysis buffer (20 mM Tris [pH 7.5], 150 mM NaCl, 2 mM
EDTA, 1% NP-40, 10% glycerol and protease inhibitor
cocktail; Roche). After clearing of lysate (14,000 rpm in a
tabletop centrifuge, 45 minutes, 4C), IP was performed by
using agarose beads coupled with Flag-speciﬁc or HA-
speciﬁc antibody (Sigma) according to manufacturer’s pro-
tocol. In brief, 40 mL bead slurry were washed twice with
lysis buffer, 1 mL cell lysate was added and incubated
overnight at 4C. After 2 times washing with lysis buffer,
beads were additionally washed once with PBS and once
with lipid kinase assay buffer (20 mM Tris/HCl [pH 7.4];
5 mM MgCl2; 0.5 mM EGTA; 0.4% Triton-X 100), before
resuspension in 40 mL lipid kinase assay buffer. Ten mi-
croliters bead slurry were used for subsequent in vitro lipid
kinase assay as described.
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Indirect Immunoﬂuorescence and
Image Quantiﬁcation
Huh7-Lunet/T7 cells were seeded onto glass cover slips
in 24-well culture plates at a density of 5  1041  105
cells/well and 1 day later, cells were transfected as
described. At given time points, cells were ﬁxed with 4%
paraformaldehyde for 15 minutes and permeabilized with
0.05% Digitonin for 5 minutes. Subsequently, samples were
washed 3 times with PBS and incubated for 20 minutes in
3% bovine serum albumin (except for PI4P staining). Pri-
mary antibodies were added for 1 hour at room tempera-
ture. After 3 times washing with PBS, cells were treated
with Alexa Fluor 488– or Alexa Fluor 546–conjugated sec-
ondary antibodies (Molecular Probes, Invitrogen) targeting
rabbit or mouse IgG/IgM domains (dilution 1:1,000 in 1%–
3% bovine serum albumin) for 1 hour at room temperature
in complete darkness. In case of lipid droplet staining,
BODIPY (Molecular Probes, Karlsruhe, Germany) was added
at a dilution of 1:50 to secondary antibody solution. Cells
were again washed 3 times with PBS and nuclear DNA was
stained with 40,60-diamidino-2-phenylindole (Molecular
Probes; dilution 1:3,000) for 1 minute at room temperature.
After washing 3 times with PBS and once with water,
samples were mounted on glass slides with FluormountG
(Southern Biotechnology Associates, Birmingham, AL) or
Vectashield (Vector Laboratories Inc., Burlingame, CA).
Coverslips were sealed with nail polish and analyzed using
a Leica SP2 confocal laser scanning microscope (Leica,
Heidelberg, Germany) or a PerkinElmer ERS-6 TE-2000
spinning disk inverted confocal microscope.
For quantiﬁcation of immunoﬂuorescence signals of
PI4P, whole-cell recordings consisting of z-stacks with 20
consecutive images were z-projected according to their
maximum intensity and quantiﬁed using the Image J soft-
ware package (version 1.46r; IntDen read-out) as previ-
ously published.12,26 NS5A and PI4KIIIa colocalization was
determined using the “Manders coefﬁcients” plugin of Im-
age J. For NS5A and LD colocalization we used the plugin
“Colocalization Finder” of Image J. For illustration purposes,
images were autocontrasted, merged and cropped with
Image J.
Electron Microscopy
Huh7-Lunet/T7 cells were seeded onto glass coverslips
in a 24-well culture plate at a density of 1  105 cells/well.
One day later, cells were transfected with pTM-based
expression vectors and treated with DMSO, BMS-553, or
AL-9 either directly before transfection (referred to as co-
treatment) or 6 hours post transfection (referred to as
posttreatment). After a total treatment period of 20 hours,
cells were washed with PBS and ﬁxed for 30 minutes with
2.5% glutaraldehyde in 50 mM sodium cacodylate buffer
[pH 7.2] containing 1 M KCl, 0.1 M MgCl2, 0.1 M CaCl2, and
2% sucrose. After ﬁxation, samples were washed 5 times
with 50 mM cacodylate buffer. Cells were post ﬁxed with
2% OsO4 in 50 mM cacodylate buffer on ice for 40 minutes
in the dark. After washing samples with water, they were
treated for 30 minutes with 0.5% uranyl acetate dissolved
in water, rinsed thoroughly with water, and dehydrated at
room temperature in a graded ethanol series (40%, 50%,
60%, 70%, and 80% for 5 minutes each time and then 95%
and 100% for 20 minutes each time). Cells were immersed
in 100% propylene oxide and immediately embedded in an
araldite-epon mixture (Araldite 502/Embed 812 kit; Elec-
tron Microscopy Sciences, Hatﬁeld, PA). After polymeriza-
tion at 60C for 2 days, the coverslips were removed.
Sectioning of the embedded cell monolayer into 60-nm
sections was performed by using a Leica Ultracut UCT
microtome and a diamond knife. The sections were coun-
terstained with 3% uranyl acetate in 70% methanol for 5
minutes, 2% lead citrate in water for 2 minutes, and
examined with a Zeiss EM 10 transmission electron mi-
croscope at 60 kV (Zeiss, Gottingen, Germany). DMV di-
ameters and area of cell proﬁles were measured using the
iTEM application software (version 5.2; Olympus, Shinjuku,
Tokio). DMV number was determined by analysis of mul-
tiple cell proﬁles using the iTEM and Image J software
(version 1.46r) packages. For correlative light-electron mi-
croscopy, Huh7-Lunet/T7 cells were seeded into glass-
bottom culture dishes containing photo-etched gridded
coverslips (MatTek Corporation, Ashland, MA) and trans-
fected with pTM constructs expressing the wt or resistance
mutation (Y93H) containing NS3-5B polyprotein, each with
a gfp insertion in DIII of NS5A. Cells were co-treated as
described with 50 EC90 BMS-553 and after 20 hours,
living cells were analyzed by ﬂuorescence microscopy using
a Leica SP2 confocal laser scanning microscope. NS5A-
containing gfp-positive cells were identiﬁed, imaged, and
their position on the gridded coverslip was documented.
Immediately thereafter, cells were ﬁxed and embedded as
described. For additional electron microscopy analysis, a
small area covering the region of interest was trimmed and
60-nm-thick sections were collected on formvar-coated slot
grids. Electron microscopy images of cells of interest were
acquired using the Zeiss EM 10 transmission electron mi-
croscope and correlated with confocal microscope images.
For illustration purposes, images were adapted using Image
J software (version 1.46r) and Adobe Photoshop (version
12.1.1).
In Silico Docking Experiments
To gain insight into NS5A inhibitor binding sites on
available structures of NS5A dimer proteins and on inhibi-
tor binding afﬁnity, in silico docking was performed using
the Sybyl X 2.0 program included in the molecular modeling
suite software package (Tripos, Inc.). Inhibitor molecules
were modeled with this program and were energetically
minimized using the MMFF94 forceﬁeld with a dielectric
constant set to 80 and stored into a database. The 2 avail-
able x-ray crystal structures of the NS5A DI dimer27,28 were
acquired from the Protein Data Bank (PDB; entries 1ZH1
and 3FQQ, respectively). The corresponding Y93H mutants
were built using the biopolymer module of the Sybyl X
molecular modeling suite and minimized by 1000 steps
with the Tripos forceﬁelds and Gasteiger–Marsilli partial
charges. The Docking simulation was computed using
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SurﬂeX-Dock program29 in ﬂexible mode included in Sybyl.
To increase the docking capabilities and to obtain reliable
conformations, the complete face of the protein was taken to
generate the protomol ﬁelds with a threshold set to 0.5 and
a bloat 10 Å for docking. The maximum number of confor-
mations for a fragment was increased to 100 and the
maximum of rotatable bonds to molecule set to 200. The
CSoreTM software was used for ranking the afﬁnity of
compounds bound to a protein with consensus scoring
(Chemscore, D_score, G_Score, and PMF_Score). The SMILES
strings of the four compounds used for docking studies
were provided by Steve J. Matthews and David Langley, who
published these structures recently.
Molecular Modeling and Structure
Representation
The 3-dimensional models of NS5A were generated from
atomic coordinates reported at the PDB (entries 1ZH1 and
3FQQ for the “clam-like” and “back-to-back” structures,
respectively). The phospholipid membrane is a simulated
model of a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
bilayer obtained from D. P. Tieleman (http://moose.bio.
ucalgary.ca). The position of the N-terminal amphipathic a-
helix in-planemembrane anchor of NS5A (PDB entry 1R7E) at
the membrane interface was deduced from molecular
dynamics simulations in a 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine bilayer (N. Sapay, R. Montserret, D. Mor-
adpour, C. Chipot, and F. Penin, unpublished). Figures were
generated from structure coordinates deposited in the PDBby
using Visual Molecular Dynamics (http://www.ks.uiuc.edu/
Research/vmd/)30 and rendered with POV-Ray (http://
www.povray.org).
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Supplementary Figure 1. (A) Dose-response curves for BMS-553. Left panel: Cells containing stable ﬁreﬂy luciferase reporter
replicons of genotype 2a (replicon JFH1) or genotype 1b (replicon Con1ET) were incubated 24 hours post seeding with
increasing concentrations of BMS-553 for 72 hours. Cells were lysed and luciferase activity was determined. Values (relative
light units [RLU]) were normalized to DMSO-treated mock samples (set to 100%). Right panel: Huh7.5 cells were infected with
one TCID50/cell of full-length Renilla luciferase reporter virus (JcR-2a),
12 and treated with different concentrations of BMS-553
6 hours post infection. Luciferase activity in cell lysates was determined 72 hours later. Background values of noninfected cells
were subtracted. EC50/EC90 values are summarized in the table. (B) Cytotoxicity of daclatasvir derivatives BMS-553, BMS-671,
and BMS-690. Huh7-Lunet cells were treated with compounds speciﬁed in the top right for 1 or 3 days. Culture supernatants
and cell lysates were harvested and used for measurements of lactate dehydrogenase (LDH) via a coupled quantitative
enzymatic assay. LDH release (ratio supernatant/cells) was normalized to DMSO-treated control cells (mock), which was set to
100%. Mean values of 2 experiments are shown. Used compound concentrations and the respective EC90 values of BMS-553
(determined by HCV replication inhibition assay) are speciﬁed in the bottom. (C) Dose–response curves of biotin-tagged
compound derivatives BMS-671 and BMS-690 (left and right panel, respectively). The assay was performed, as described
in Figure 1B. EC50 as well as EC90 values were determined using the GraphPad Prism software package (version 5.03). All
values are summarized in the table below the left graph. Note that BMS-690 is an inactive stereoisomer of BMS-671 that does
not inhibit HCV replication.
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Supplementary Figure 2. Impact of BMS-553 on NS5A
abundance and phosphorylation status. Huh7 cells were
infected with Jc1 wt or the Jc1 Y93H-resistance mutant.
Twenty-four hours later cells were treated with 5 or 50
EC90 BMS-553 or mock-treated with DMSO. For comparison,
cells treated with 5 EC50 of the NS3 protease inhibitor
telaprevir were analyzed in parallel. Samples were harvested
6, 12, and 24 hours after drug treatment. NS5A and glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) (loading
control) levels were determined by Western blot using
monospeciﬁc antibodies. The lower and upper NS5A-speciﬁc
bands corresponds to basal (p56) and hyperphosphorylated
(p58) NS5A, respectively (indicated with asterisks). The ratio
of p58/total NS5A normalized to the loading control GAPDH
(designated % p58) is given below each lane. Values deter-
mined for mock-treated samples were set to 100%.
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Supplementary Figure 3. (A) T7-based expression system. Huh7-Lunet/T7 cells stably expressing T7 RNA polymerase
(T7 pol) were transfected with constructs containing a T7 promoter (T7) and terminator (T7 term) and the internal ribosome entry
site of encephalomyocarditis virus allowing efﬁcient expression of the HCV NS3-5B polyprotein. Note that the 30 untranslated
region (UTR) was included in all polyprotein expression constructs because of the reported binding of NS5A to the 30 UTR.17 N,
nucleus. (B) BMS-553 does not affect half-life of NS5A proteins. Huh7-Lunet/T7 cells were transfected 1 day after seeding with
a construct encoding the wt NS3-5B polyprotein or an empty vector. After 20 hours, samples were either mock-treated with
DMSO or treated with 5 or 50 EC90 BMS-553 and starved for 1 hour. Subsequently proteins were radiolabeled meta-
bolically with [35S] methionine/cysteine for 1 hour (pulse). After removal of radioactive medium and intensive washing, cells
were incubated with nonradioactive medium (chase) for indicated periods. Throughout the pulse and chase period, compound
treatment was continued. Cells were washed, lysed, and NS5A was isolated by immunoprecipitation (IP) using agarose beads
coupled to monospeciﬁc NS5A antibody. Captured complexes were analyzed by SDS-PAGE and phospho-imaging. The 2
NS5A phospho-isoforms (p56 and p58) are indicated with asterisks. (C) Quantiﬁcation of p56 (left panel) and p58 (right panel)
relative to total NS5A amounts was done using the QuantityOne software package (version 4.6.2). For each time point, values
of mock-treated cells were set to 100%. (D) Stability of p56 (left panel) and p58 (right panel). Protein amounts were determined
as described. Values determined at time point zero were set to 100%. Mean values of 2 experiments are shown.
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=Supplementary Figure 4. Replication competence and BMS-553 sensitivity of tandem-NS5A reporter replicons. (A) Sche-
matic of the subgenomic JFH1-derived tandem NS5A luciferase reporter replicon (upper panel). This construct comprises
(from 50 to 30 end): the 50 nontranslated region of HCV, a ﬁreﬂy luciferase gene (Luc), the internal ribosome entry site of the
encephalomyocarditis virus, the coding region for NS3 to NS5B with a tandem NS5A cassette and the HCV 30 nontranslated
region. The tandem NS5A cassette consists of differently tagged NS5A copies (HA- and gfp-tag, respectively), separated in-
frame by the region encoding the 2a peptide from the foot and mouth disease virus. A blow-up specifying the insertion sites of
the HA- and gfp-tag (blue and green triangle, respectively) relative to the position of D I, II, and III of NS5A is shown in the lower
panel. The corresponding amino acid numbers of each NS5A sequence are indicated. Two variants of this tandem NS5A
replicon were used. Tandem wt–wt contains 2 wt NS5A copies; tandem Y93H–Y93H contains 2 NS5A copies each with this
primary resistance mutation. (B) Replication kinetics of tandem NS5A replicons in comparison with the parental nontandem
replicons (sgJFH1-Luc and sgJFH1-Luc Y93H, respectively). Huh7-Lunet cells were transfected with in vitro transcribed RNA
of replicons speciﬁed in the bottom and luciferase activity in lysates of cells harvested at indicated time points post elec-
troporation (p.e.) was determined. For each construct, values (relative light units [RLU]) were normalized to the corresponding
4-hour value that reﬂects transfection efﬁciency and was set to 100%. Cells transfected with the replication-incompetent
genotype 2a mutant sgJFH1-Luc DGDD were analyzed in parallel to determine assay background. Note that the tandem
NS5A replicon is viable. In addition, replication ﬁtness is strongly reduced by the Y93H resistance mutation, but this is the case
for tandem NS5A, as well as parental single-NS5A replicon constructs. (C) BMS-553 sensitivity of tandem NS5A replicons
(tandem wt–wt and tandem Y93H–Y93H) relative to the parental nontandem constructs (sgJFH1-Luc and sgJFH1-Luc Y93H).
Huh7-Lunet cells were transfected with corresponding in vitro RNA transcripts and 24 hours later BMS-553 or DMSO was
added at different concentrations. Luciferase activity (RLUs) contained in cell lysates was determined after 72 hours of
treatment. Values were normalized to DMSO-treated mock cells (set to 100%). Effective concentrations for the wt replicons are
summarized in the table below. Note that the tandem Y93H-Y93H replicon is completely resistant to BMS-553 that otherwise
efﬁciently suppressed replication of the wt tandem NS5A replicon (tandem wt–wt) analogous to the parental JFH1 reporter
replicon sgJFH1-Luc.
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=Supplementary Figure 5. Docking results for BMS-553 and daclatasvir to the back-to-back dimer of DI.28 (A) High- and low-
ranked poses for BMS-553 (in red and blue, respectively) within the ribbon diagram of the 2 subunits (colored yellow and light
gray) of the NS5A DI model (PDB entry 3FQQ) associated with a phospholipid membrane represented as a simulated model of
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC). The in-plane position of the amino-terminal amphipathic a-helices
(AH; PDB entry 1R7E) of NS5A at the membrane interface (top left panel) was deduced from molecular dynamics simulations in
the POPC bilayer. Note that the orientation of the AH relative to DI is arbitrary. Polar heads and hydrophobic tails of phos-
pholipids (stick structures) of the membrane are colored light yellow and light gray, respectively, and are only shown in the top
left panel of this ﬁgure for clarity. In this DI crystal structure, residues 32 and 33, which are the N-terminal residues of subunits
A and B, respectively, are represented as van der Waals spheres and colored pink and magenta, respectively. Residue Y93,
L31, and M28 reported to confer resistance to NS5A inhibitors are indicated by bold letters and colored green, blue and yellow,
respectively. Residues 37, 54, 58, for which mutations have been associated with secondary resistance to daclatasvir, but do
not confer resistance by themselves, are shown in orange, cyan, and blue, respectively. Note that all domains and structures
are drawn to scale. Note also the supposed membrane-proximal positions of the resistance mutations and the docked in-
hibitor. The superimposition of various high and low ranked poses on the membrane-proximal surface of this model is shown
in the bottom right panel (line representation). This view as well as the other membrane-proximal views (bottom left andmiddle
panel) and side views (surface representation, top middle and right panel) show that high- and low-ranked poses occupy
overlapping symmetrical positions in the cleft located at the junction of the 2 subunits. Both side views show that one edge of
BMS-553 partly extends outside the cleft. (B) Docking results for daclatasvir. High-ranked and low-ranked poses are colored
violet and orange, respectively. As detailed for BMS-553 in (A), daclatasvir poses occupy overlapping symmetrical positions in
the dimer cleft located at the junction of the 2 subunits.
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Supplementary Figure 6. High-resolution image of interac-
tion of daclatasvir with NS5A residues involved in NS5A in-
hibitor resistance. (A) Back-to-back dimer structure of NS5A
DI (PDB accession no. 3FQQ; surface representation)
showing a representative high-ranked pose of daclatasvir
(violet) docked into the cleft located at the junction of the 2
subunits (yellow and light gray). (B) Clam-like dimer structure
of NS5A DI showing a representative high-ranked pose of
daclatasvir docked on the rather ﬂat surface of 1 of the 2
subunits (cyan and mauve). In both panels, residues involved
in daclatasvir–NS5A interactions31 and associated with pri-
mary or secondary resistance to daclatasvir are shown as van
der Waals spheres. Note the interactions between daclatasvir
and several residues involved in drug resistance, especially
the stacking of aromatic rings between daclatasvir and the
side chain of tyrosine 93. For additional details see legend to
Supplementary Figure 5.
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Supplementary Figure 7. Docking results for BMS-553 and daclatasvir to the clam-like dimer of DI.27 (A) High and low rank
poses for BMS-553 (in red and blue, respectively) within the ribbon diagram of the 2 subunits (colored yellow and light gray) of
the NS5A DI model (PDB entry 1ZH1) are shown. Also depicted in the top left image are the amino-terminal amphipathic a-
helices (AH; PDB entry 1R7E; top left panel) and the associated phospholipid membrane (for details see legend to
Supplementary Figure 5). Note that the positions of amphipathic helices relative to DI are arbitrary. The color coding of res-
idues represented as van der Waals spheres is the same as in Supplementary Figure 5. The superimposition of various high
and low ranked poses on the membrane-proximal surface of this model is shown in the bottom right panel. This view as well as
the other membrane-proximal views (bottom left and middle panel) and side views (surface representation, top right panel)
show that high- and low-ranked poses contact the aromatic side chain of residues Y93, but occupy asymmetrical positions on
the relatively ﬂat surface of this dimer. Note that high-ranked poses mainly locate on 1 subunit (cyan), and the low-ranked
poses extend to both subunits. (B) Docking results for daclatasvir. High-ranked and low-ranked poses are colored violet
and orange, respectively. As described for BMS-553 in panel (A), daclatasvir high- and low-ranked poses occupy asymmetrical
positions on the surface of this dimer model, with high-ranked poses mainly located on 1 subunit (cyan), and the low-ranked
poses extend on both subunits. Note the limited contact of low-ranked poses with the aromatic ring of Y93. For additional
details, see legend to Supplementary Figure 5.
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=Supplementary Figure 8. NS5A–PI4KIIIa colocalization is
not affected by BMS-553. (A) Huh7-Lunet/T7 cells expressing
wt (upper panel) or Y93H-containing NS3-5B polyprotein
(Y93H, lower panel) were treated with 5 or 50 EC90 BMS-
553 or mock-treated with DMSO for 20 hours starting 6 hours
after transfection. Representative immunoﬂuorescence
images of NS5A (left column) and ectopically expressed
HA-PI4KIIIa (middle column) as detected with protein- and
tag-speciﬁc antibodies, respectively, are shown. Nuclear
DNA was stained with 40,60-diamidino-2-phenylindole. High-
lighted areas in merged images (right column) are shown
in the blow up on the right of each merge. NS5A, red;
HA-PI4KIIIa, green; nuclear DNA, blue. (B) Colocalization
between NS5A and HA-PI4KIIIa. Raw data were used to
determine Mander’s correlation coefﬁcient for >50 cell pro-
ﬁles by using Image J. For illustration purposes, images were
autocontrasted, merged, and cropped using Image J. Note
that differences between all conditions were not signiﬁcant.
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Supplementary Figure 9. (A) In vitro lipid kinase activity of PI4KIIIa associated with NS5A. Huh7-Lunet/T7 cells were
transfected with wt or resistant (Y93H) HCV polyprotein expression constructs with or without overexpression of HA-PI4KIIIa,
as speciﬁed in the bottom of each panel. To facilitate immunocapture, a fully replication competent NS5A variant with a Flag-
tag inserted in-frame into DII20 was used. Cells were treated with DMSO (mock treatment) or 50 EC90 BMS-553 for 20 hours
starting 6 hours after transfection. IP was performed with Flag-speciﬁc (left and middle panel) or HA-speciﬁc (right panel)
agarose beads. Captured complexes were analyzed for PI4KIIIa lipid kinase activity in vitro. Note that in the middle panel only
the activity of endogenous PI4KIIIa was studied, and in the left and the right panel, activity of endogenous plus ectopically
expressed HA-PI4KIIIa was analyzed. Data are given in counts per minute (cpm). Background counts were subtracted. Values
obtained with mock-treated samples were set to 100%. (B) Immunoﬂuorescence (IF) staining of NS5A and PI4P using protein-
and lipid-speciﬁc antibody, respectively. Huh7-Lunet/T7 cells expressing NS3-5B wt or resistant (Y93H) polyprotein or an
empty vector were treated with DMSO (mock control) or 5 or 50 EC90 BMS-553. Treatment started directly before
transfection and lasted for 20 hours (co-treatment protocol). Fixed cells were stained for PI4P and NS5A using mouse
monoclonal antibodies. Nuclear DNA was stained with 40,60-diamidino-2-phenylindole. Representative images are shown. For
quantiﬁcation of immunoﬂuorescence signals of PI4P, z-stacks were quantiﬁed using Image J. The y-axis displays intensity
density (IntDen) in arbitrary units (AU). For each sample, >40 cells were analyzed. Mean values of 3 independent experiments
are shown. NS5A, red; PI4P, green; nuclear DNA, blue.
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Supplementary Figure 10. Comparable morphology of the MW in cells expressing the NS3-5B polyprotein or containing a
replicating HCV genome. (A) Cells were transfected with the HCV genome Jc1 (left panel) or a pTM-based DNA construct
encoding the NS3-5B polyprotein of JFH1 (right panel) and 48 hours (Jc1) or 24 hours (pTM) later cells were processed for
transmission electron microscopy (EM) as described in the legend to Figure 6 or Figure 4, respectively. Representative EM
images are shown. (B) Quantiﬁcation of DMV diameter (left panel) or number (right panel) as described in the legend to Figure 4.
(C) Immunoﬂuorescence staining of NS5A in cells prepared as described. Nuclear DNA was stained with 40,60-diamidino-2-
phenylindole. Representative images are shown. For illustration purposes, images were autocontrasted, merged, and crop-
ped using Image J. Cells highlighted with a white box are magniﬁed below each image. NS5A, red; nuclear DNA, blue. Note
that because of the reported interaction of NS5A with the HCV 30 untranslated region (UTR), this RNA element was included in
all polyprotein expression constructs.17 However, we found that the 30UTR is not required for generation and morphology of
membrane alterations because constructs lacking the 30UTR induced comparable membrane alterations (data not shown).
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Supplementary Figure 11. BMS-553 treatment does not
affect transfection efﬁciency. Immunoﬂuorescence staining of
NS5A in Huh7-Lunet/T7 cells expressing the wt or the Y93H-
containing NS3-5B polyprotein. Cells were mock-treated with
DMSO or treated with 5 or 50 EC90 BMS-553 either 6
hours post transfection (A) or directly at transfection (B). Cells
were ﬁxed after 20 hours of treatment and indirectly immu-
nostained with NS5A-speciﬁc antibody. Nuclear DNA was
stained with 40,60-diamidino-2-phenylindole. NS5A, red; nu-
clear DNA, blue.
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Supplementary Figure 12. BMS-553, but not AL-9 co-treatment completely abrogates membranous web formation. (A)
Detection of the HCV-induced membranous web in cells expressing wt or resistant (Y93H) NS3-5B polyprotein. Cells were co-
treated with DMSO (mock control), BMS-553 (5 or 50 EC90), or AL-9 (5 or 50 EC50). Treatment of cells with given
compound started directly at transfection (referred to as co-treatment) and was continued until cell harvest (total treatment
duration 20 hours). Representative images are shown. Regions encircled with yellow lines highlight membranous web
structures predominantly containing DMVs. Corresponding quantiﬁcation data can be found in Figure 5.
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Supplementary Figure 13. Impact of BMS-553 treatment on accumulation of NS5A around lipid droplets (LDs). Huh7-Lunet/
T7 cells transfected with the NS3-5B polyprotein expression construct or the empty vector (not shown) were mock-treated
with DMSO or treated with 5 or 50 EC90 BMS-553 for 20 hours starting 6 hours after transfection. (A) Immunoﬂuores-
cence staining of NS5A with a monospeciﬁc antibody and staining of LDs with the lipophilic dye Bodipy. Nuclear DNA was
stained with 40,60-diamidino-2-phenylindole. Representative images are shown. Areas highlighted with the white-dashed boxes
are magniﬁed in the right of each row. NS5A, red; LDs, green; nuclear DNA, blue. (B) Quantitative analysis of raw data with
respect to NS5A–LD colocalization by using Image J software (version 1.46r). For each condition >20 cell proﬁles were
analyzed. For illustration purposes, images were autocontrasted, merged, and cropped using Image J.
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